Search

Your search for "ANVS" returned the following results.
Filter Results:
News Articles

Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference

September 25, 2024

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), participated in the H.C. Wainwright 26th Annual Global Investment Conference, held virtually, as well as in-person at the Lotte New York Palace Hotel in New York City, Sept. 9-11, 2024 […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

September 20, 2024

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

September 5, 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced participation at the H.C. Wainwright 26th Annual Global Investment Conference. The conference, held virtually and in person, is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New […]

Press Releases

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 5, 2024

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients

August 30, 2024

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), recently welcomed four seasoned professionals to its executive team. “Annovis Bio is excited about the new additions and confident that these highly experienced professionals will significantly contribute to […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

August 26, 2024

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter ended June 30, 2024. The company reported productive recent months, with encouraging data on lead compound buntanetap’s performance […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

August 20, 2024

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association International Conference(R) 2024 (AAIC(R)) in Philadelphia. Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of the company detailed these […]

InvestorNewsBreaks

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months

August 15, 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released financial results for its second quarter ended June 30, 2024, and provided a business update. According to the update, results from the company’s completed Phase 2/3 AD study showed that buntanetap significantly […]

Press Releases

Annovis Bio Reports Second Quarter Financial Results and Provides Business Update

August 15, 2024

MALVERN, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) — via IBN — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced financial results for the second quarter ended June 30, 2024, and provided a […]

InvestorNewsBreaks

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Given $21.00 Price Target by EF Hutton

August 14, 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), recently had its price target set at $21.00. The price target was issued by Jason Kolbert from EF Hutton on August 13, 2024. At the time of the announcement, Annovis Bio was trading at […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement

August 14, 2024

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced new preclinical data demonstrating lead compound buntanetap’s potential to synergistically enhance cognition when used in combination with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity(R)) in a mouse model of Alzheimer’s disease (https://ibn.fm/9WpKW). GLP-1 agonists, such as dulaglutide, are known for their ability to […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap

August 12, 2024

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with its lead drug candidate, buntanetap. Initially filed in 2016, the patent covered treatments for various nerve injuries, including TBI, stroke, and spinal cord injuries, but required division into individual patents by […]

InvestorNewsBreaks

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model

August 8, 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data regarding buntanetap, its lead compound. According to the report, the date demonstrates the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide […]

InvestorNewsBreaks

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows

August 7, 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition

August 6, 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting preclinical data regarding its lead compound, buntanetap. According to the announcement, the results show the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) […]

Press Releases

Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

August 6, 2024

MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined […]

InvestorNewsBreaks

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Featured in Latest Bell2Bell Podcast, Recorded Live at AAIC 2024

August 5, 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is spotlighted in the latest episode of The Bell2Bell Podcast, released by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. The episode, which featured Annovis Bio […]

Press Releases

IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024

August 5, 2024

LOS ANGELES, Aug. 05, 2024 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer’s Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN’s ongoing efforts to […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) Announces FDA Approval to Transition to New Form of Buntanetap for Future Clinical Trials

July 30, 2024

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s, just announced that the U.S. Food and Drug Administration (“FDA”) has given approval for Annovis to switch to a new solid form of buntanetap for their future clinical trials (https://ibn.fm/KfHve). In June 2024, Annovis announced […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate

July 24, 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent covers methods of treating acute traumatic brain injuries (“TBI”) and preventing nerve cell death with its lead drug candidate, buntanetap. Buntanetap (formerly known […]

Press Releases

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

July 24, 2024

MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

July 23, 2024

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

July 19, 2024

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease and Parkinson’s Disease, has released new data from its Phase III study of buntanetap for early Parkinson’s Disease. The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

July 17, 2024

Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is continuing to make significant strides in the field of neurodegenerative diseases with its latest patent filings. The recent announcement is the filing of a […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap

July 16, 2024

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to a new solid form of buntanetap in future clinical trials. “In June 2024, Annovis announced […]

Press Releases

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

July 16, 2024

MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to […]

InvestorNewsBreaks

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team

July 9, 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has announced that four new executives will be joining the company’s management team. The four new leaders include Mark White as chief business officer; Alexander Morris, PhD, as director of strategic communications; […]

Press Releases

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team

July 9, 2024

MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is pleased to announce the addition of four accomplished professionals to its executive team.  […]

InvestorNewsBreaks

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast

July 2, 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD study. According to the report, study findings indicate that buntanetap, the company’s proprietary drug candidate, is safe and effective in improving motor and […]

Press Releases

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap

July 2, 2024

Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.  Parkinson’s patients with substantial cognitive decline exhibited a very pronounced improvement.Buntanetap showed statistical improvement in the MDS-UPDRS Part II, Part III, Part II+III and Total scores in Parkinson’s patients with a >3-year diagnosis.Buntanetap showed the same statistical improvement in MDS-UPDRS […]

News Articles

Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease

June 28, 2024

June is Alzheimer’s & Brain Awareness Month, a time dedicated to raising awareness about Alzheimer’s disease and other forms of dementia, as well as the importance of brain health. Even though the month is almost over, Annovis Bio’s commitment to the Alzheimer’s community goes on. Annovis Bio (NYSE: ANVS), a late-stage drug platform company, recently […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap

June 27, 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), is announcing the filing of a provisional patent. This patent covers the manufacturing process of new solid forms of buntanetap (formerly known as Posiphen or ANVS401), which targets neurodegeneration by inhibiting the formation of […]

Press Releases

Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap

June 27, 2024

MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announced today the filing of a provisional patent covering the manufacturing process of new solid forms of […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter

June 26, 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed a patent with the U.S. Patent and Trademark Office. The patent covers novel solid forms of buntanetap, selecting the best crystal and building upon the provisional patent the company filed […]

Press Releases

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

June 26, 2024

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate

June 25, 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), is hosting an investor webcast. During the webcast, Annovis Bio officials will discuss recent developments and future plans for its lead drug candidate, Buntanetap, which targets neurodegeneration by inhibiting the formation of multiple neurotoxic […]

Press Releases

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data

June 25, 2024

MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host an investor webcast to discuss recent developments and […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024

June 18, 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting results from its latest Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 (“AAIC”). The conference is slated to run from July 28–Aug. 1, 2024, in Philadelphia as well as online. […]

Press Releases

Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024

June 18, 2024

MALVERN, Pa., June 18, 2024 (GLOBE NEWSWIRE) — via IBN — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), is pleased to announce that it has been selected to present the data from its latest Alzheimer’s study in […]

InvestorNewsBreaks

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call

June 11, 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting the results of its recent phase 2/3 Alzheimer’s study. The study was designed to evaluate Buntanetap, the company’s lead drug candidate. According to the report, key findings indicate that Buntanetap showed […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).